ATE541568T1 - Infusionsflüssigkeit zur behandlung der anämie bei dialysepatienten - Google Patents
Infusionsflüssigkeit zur behandlung der anämie bei dialysepatientenInfo
- Publication number
- ATE541568T1 ATE541568T1 AT07251707T AT07251707T ATE541568T1 AT E541568 T1 ATE541568 T1 AT E541568T1 AT 07251707 T AT07251707 T AT 07251707T AT 07251707 T AT07251707 T AT 07251707T AT E541568 T1 ATE541568 T1 AT E541568T1
- Authority
- AT
- Austria
- Prior art keywords
- patients
- amino acid
- infusion fluid
- anemia
- essential amino
- Prior art date
Links
- 239000003978 infusion fluid Substances 0.000 title abstract 3
- 208000007502 anemia Diseases 0.000 title abstract 2
- 238000000502 dialysis Methods 0.000 title abstract 2
- 229940024606 amino acid Drugs 0.000 abstract 3
- 235000001014 amino acid Nutrition 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 235000020776 essential amino acid Nutrition 0.000 abstract 3
- 239000003797 essential amino acid Substances 0.000 abstract 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 abstract 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 abstract 1
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 abstract 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229930064664 L-arginine Natural products 0.000 abstract 1
- 235000014852 L-arginine Nutrition 0.000 abstract 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- 229930182844 L-isoleucine Natural products 0.000 abstract 1
- 239000004395 L-leucine Substances 0.000 abstract 1
- 235000019454 L-leucine Nutrition 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- 229930195722 L-methionine Natural products 0.000 abstract 1
- 229930182821 L-proline Natural products 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 229960003767 alanine Drugs 0.000 abstract 1
- 230000001668 ameliorated effect Effects 0.000 abstract 1
- 229960005261 aspartic acid Drugs 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 229960002989 glutamic acid Drugs 0.000 abstract 1
- 229960002449 glycine Drugs 0.000 abstract 1
- 229960002885 histidine Drugs 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 229960003136 leucine Drugs 0.000 abstract 1
- 229960004452 methionine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000003715 nutritional status Nutrition 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 229960002429 proline Drugs 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229960001153 serine Drugs 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 abstract 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 abstract 1
- 229960002898 threonine Drugs 0.000 abstract 1
- 229960004441 tyrosine Drugs 0.000 abstract 1
- 229960004295 valine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006119694 | 2006-04-24 | ||
| JP2006124235 | 2006-04-27 | ||
| JP2006171886A JP5316918B2 (ja) | 2006-04-24 | 2006-06-21 | 透析患者用輸液剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE541568T1 true ATE541568T1 (de) | 2012-02-15 |
Family
ID=38319570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07251707T ATE541568T1 (de) | 2006-04-24 | 2007-04-24 | Infusionsflüssigkeit zur behandlung der anämie bei dialysepatienten |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20070281985A1 (de) |
| EP (1) | EP1849466B8 (de) |
| JP (1) | JP5316918B2 (de) |
| AT (1) | ATE541568T1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5376206B2 (ja) | 2007-12-05 | 2013-12-25 | 富士フイルム株式会社 | 位置特定システムおよびプログラム |
| AU2009268742C1 (en) | 2008-07-07 | 2013-11-28 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| JPWO2010106871A1 (ja) * | 2009-03-19 | 2012-09-20 | 国立大学法人富山大学 | 浸透圧調整剤 |
| GB2489163A (en) * | 2010-01-04 | 2012-09-19 | Pentec Health Inc | Nutritive compositions and methods of using same |
| US20160309753A1 (en) | 2015-04-21 | 2016-10-27 | Calwood Nutritionals, Llc | Methods of ameliorating post-dialysis washout and nutritional supplements for use in such methods |
| CU20200106A7 (es) * | 2018-06-20 | 2021-08-06 | Axcella Health Inc | Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias |
| US20220347141A1 (en) * | 2019-09-17 | 2022-11-03 | Yale University | Methods of treating phosphate concentration disorders with l-baiba |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6830692B1 (en) * | 1999-09-20 | 2004-12-14 | Degussa Ag | Amino acid composition for hemodialysis |
| US6787039B2 (en) * | 2001-01-26 | 2004-09-07 | Degussa Ag | Amino acid composition for hemodialysis |
| US20050148647A1 (en) * | 2003-10-31 | 2005-07-07 | Landry Donald W. | Hemodialysis solutions and uses thereof |
| EP1726303A4 (de) * | 2004-03-19 | 2011-03-02 | Ajinomoto Kk | Therapeutisches mittel gegen nierenanämie |
-
2006
- 2006-06-21 JP JP2006171886A patent/JP5316918B2/ja active Active
-
2007
- 2007-04-24 US US11/790,159 patent/US20070281985A1/en not_active Abandoned
- 2007-04-24 EP EP07251707A patent/EP1849466B8/de active Active
- 2007-04-24 AT AT07251707T patent/ATE541568T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1849466B8 (de) | 2012-11-07 |
| JP2007314497A (ja) | 2007-12-06 |
| EP1849466B1 (de) | 2012-01-18 |
| JP5316918B2 (ja) | 2013-10-16 |
| EP1849466A3 (de) | 2007-12-26 |
| US20070281985A1 (en) | 2007-12-06 |
| EP1849466A2 (de) | 2007-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008081582A1 (ja) | 容器詰飲料 | |
| ATE541568T1 (de) | Infusionsflüssigkeit zur behandlung der anämie bei dialysepatienten | |
| GB1507951A (en) | Amino acid formulations | |
| GR3026072T3 (en) | Adolescent dietary composition | |
| US7645796B2 (en) | Amino acid composition promoting collagen synthesis | |
| ATE365212T1 (de) | Verfahren zur fermentativen herstellung von l- histidin durch aminochinolin-resistente bakterienstämme der gattung escherichia | |
| SE7907393L (sv) | Aminosyralosning for intravenos neringstillforsel | |
| JP2011523626A5 (de) | ||
| EP0872180A4 (de) | Zusammensetzung eines mediums für externe befruchtung | |
| CN108721596A (zh) | 一种复方氨基酸维生素注射液及其应用 | |
| RU2004137198A (ru) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА Enterobacteriaceae, В КОТОРОЙ ИНАКТИВИРОВАН ГЕН yafA | |
| JPS61247354A (ja) | 栄養素組成物 | |
| ATE557096T1 (de) | L-tryptophan produzierendes bakterium und verfahren zur produktion von l-tryptophan | |
| JP2010513259A5 (de) | ||
| DK0399341T3 (da) | Vandigt præparat til parenteral ernæring | |
| RU2006143864A (ru) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА ENTEROBACTERIACEAE, В КОТОРОЙ ОСЛАБЛЕНА ЭКСПРЕССИЯ ГЕНОВ cynT, cynS, cynX, ИЛИ cynR, ИЛИ ИХ КОМБИНАЦИИ | |
| RU2010105710A (ru) | Мутантная аденилатциклаза, днк, кодирующая ее, бактерия семейства enterobacteriaceae, содержащая указанную днк, и способ получения l-аминокислот | |
| GB1460108A (en) | Pharmaceutical preparations containing aspirin or indomethacin | |
| TH105086A (th) | ของไหลน้ำที่มีการปล่อยให้ของไหลเข้าหลอดเลือดสำหรับผู้ป่วยที่ได้รับไดอะไลซิส | |
| WO2008096846A1 (ja) | 安定同位体標識タンパク質合成用組成物及び安定同位体標識タンパク質の製造方法 | |
| TH105086B (th) | ของไหลน้ำที่มีการปล่อยให้ของไหลเข้าหลอดเลือดสำหรับผู้ป่วยที่ได้รับไดอะไลซิส | |
| EP1199355A4 (de) | Schwefelfreie enzyme | |
| RU2006123752A (ru) | СПОСОБ ПОЛУЧЕНИЯ L-АМИНОКИСЛОТ С ИСПОЛЬЗОВАНИЕМ БАКТЕРИИ СЕМЕЙСТВА Enterobacteriaceae, В КОТОРОЙ ОСЛАБЛЕНА ЭКСПРЕССИЯ ОПЕРОНА rspAB | |
| RU2017489C1 (ru) | Лекарственное средство для парентерального питания и дезинтоксикации | |
| JP2005289938A5 (de) |